belzutifan: Clinical Trials

8 trials of belzutifan, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

5 active not recruiting, 3 recruiting. 8 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	8	Active not recruiting 5, Recruiting 3

Follow belzutifan: new trials by email Literature Review of belzutifan trials Research Report on belzutifan

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) Belzutifan, Zanzalintinib, Placebo - Carcinoma, Renal Cell	Phase 3	Recruiting	Merck Sharp & Dohme LLC	758	2026-04-09	2026-10-29
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) Belzutifan, Nivolumab, Lenvatinib - Von Hippel-Lindau Disease, Malignant Neoplasms	Phase 3	Recruiting	Merck Sharp & Dohme LLC	450	2026-03-23	2026-10-21
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) Belzutifan, Zanzalintinib, Cabozantinib - Renal Cell Carcinoma	Phase 3	Recruiting	Merck Sharp & Dohme LLC	904	2025-11-26	2026-08-03
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab - Carcinoma, Renal Cell	Phase 3	Active not recruiting	Merck Sharp & Dohme LLC	251	2022-07-27	2026-08-20
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) Belzutifan, Pembrolizumab, Placebo - Carcinoma, Renal Cell	Phase 3	Active not recruiting	Merck Sharp & Dohme LLC	1800	2022-03-15	2026-05-15
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab - Carcinoma, Renal Cell	Phase 3	Active not recruiting	Merck Sharp & Dohme LLC	1688	2021-04-14	2026-10-02
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) Belzutifan, Lenvatinib, Cabozantinib - Carcinoma, Renal Cell	Phase 3	Active not recruiting	Merck Sharp & Dohme LLC	747	2021-02-25	2026-05-05
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005) Belzutifan, Everolimus - Carcinoma, Renal Cell	Phase 3	Active not recruiting	Merck Sharp & Dohme LLC	755	2020-02-27	2026-10-20

Conditions studied

Sponsors

Countries

Results publications

NIH funding